UA49782U - METHOD FOR treatment OF PATIENTS WITH malignant tumours of brain - Google Patents

METHOD FOR treatment OF PATIENTS WITH malignant tumours of brain

Info

Publication number
UA49782U
UA49782U UAU200912015U UAU200912015U UA49782U UA 49782 U UA49782 U UA 49782U UA U200912015 U UAU200912015 U UA U200912015U UA U200912015 U UAU200912015 U UA U200912015U UA 49782 U UA49782 U UA 49782U
Authority
UA
Ukraine
Prior art keywords
patients
treatment
brain
malignant tumours
autovaccine
Prior art date
Application number
UAU200912015U
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Григорий Платонович Потебня
Ольга Андреевна Танасиенко
Андрей Вячеславович Бомбин
Галина Степановна Лисовенко
Любовь Николаевна Кохановска
Василий Федорович Чехун
Original Assignee
Институт Экспериментальной Патологии, Онкологии И Радиобиологии Им. Р.Е. Кавецкого Нан Украины
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Институт Экспериментальной Патологии, Онкологии И Радиобиологии Им. Р.Е. Кавецкого Нан Украины filed Critical Институт Экспериментальной Патологии, Онкологии И Радиобиологии Им. Р.Е. Кавецкого Нан Украины
Priority to UAU200912015U priority Critical patent/UA49782U/en
Publication of UA49782U publication Critical patent/UA49782U/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

A method for treatment of patients with brain malignant tumours with antineoplastic autovaccine comprises the carrying out of immune therapy for patients with removed surgically tumour after radiation or radiation and chemotherapy by triple hypodermic introduction of autovaccine, with an interval in 7 days.A vaccine made of tumoral cells, processed with 0,05-0,20 % solution of cytotoxic pectin isolated from cultural liquid of microorganism B.subtilis B-7025, is used for treatment in quantity of 3.0 ml with revaccinations in 1 and 3 months.
UAU200912015U 2009-11-23 2009-11-23 METHOD FOR treatment OF PATIENTS WITH malignant tumours of brain UA49782U (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UAU200912015U UA49782U (en) 2009-11-23 2009-11-23 METHOD FOR treatment OF PATIENTS WITH malignant tumours of brain

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
UAU200912015U UA49782U (en) 2009-11-23 2009-11-23 METHOD FOR treatment OF PATIENTS WITH malignant tumours of brain

Publications (1)

Publication Number Publication Date
UA49782U true UA49782U (en) 2010-05-11

Family

ID=50689066

Family Applications (1)

Application Number Title Priority Date Filing Date
UAU200912015U UA49782U (en) 2009-11-23 2009-11-23 METHOD FOR treatment OF PATIENTS WITH malignant tumours of brain

Country Status (1)

Country Link
UA (1) UA49782U (en)

Similar Documents

Publication Publication Date Title
AU2018256508A1 (en) Individualized vaccines for cancer
RU2434640C2 (en) Treatment of metastatic breast cancer
PH12016500004A1 (en) Pcsk9 vaccine
PH12015500940A1 (en) Bruton`s tyrosine kinase inhibitors
MX2021001762A (en) Method and composition for stimulating immune response.
AR059982A1 (en) TUMOR THERAPY WITH AN ANTIBODY AGAINST THE VASCULAR ENDOTELIAL GROWTH FACTOR AND AN ANTIBODY AGAINST THE HUMAN TYPE 2 EPITELIAL GROWTH FACTOR RECEIVER
EP2571522A4 (en) Cancer treatment
IN2012DN02826A (en)
TW200738253A (en) Method of treating patients with a mucinous glycoprotein (MUC-1) vaccine
NZ595143A (en) Treatment regimen utilizing neratinib for breast cancer
WO2011100769A3 (en) Kinase modulators for the treatment of cancer
SG194753A1 (en) Induction of il-12 using immunotherapy
WO2014081346A3 (en) Method for cancer immunotherapy and pharmaceutical compositions based on oncolytic non-pathogenic sendai virus
UA49782U (en) METHOD FOR treatment OF PATIENTS WITH malignant tumours of brain
MX2021001288A (en) Vaccination with microvesicles derived from tumour cells for cancer treatment.
WO2023049636A3 (en) Cancer therapy compositions and uses thereof
AU2018251949A1 (en) Compounds, composition and uses thereof for treating cancer
WO2011006084A3 (en) Vaccines with oncofetal antigen/ilrp-loaded autologous dendritic cells and uses thereof
MX2012005497A (en) Tivozanib and temsirolimus in combination.
Verma et al. Cancer Vaccines in the Immunotherapy Era: Promise and Potential
UA95522C2 (en) method for treatment of patients with malignant brain tumors with antitumor vaccine
PH22019000676U1 (en) Organic mulberry leaf water extract having anticlastogenic activity and method of production thereof
MD4714C1 (en) Process for cultivation of Spirulina platensis cyanobacterium
WO2021062405A3 (en) Alpha-lactalbumin vaccination for inhibiting growth and development of male breast cancers
CN106366080A (en) Anti-melanoma compound and application thereof